AstraZeneca’s targeted treatment helps patients live longer, along with preventing cancer recurrence.
Gastric cancer is the fifth leading cause of cancer death globally, with nearly one million people diagnosed each year. Credit: Pawel Michalowski/Shutterstock.com.
AstraZeneca’s Imfinzi (durvalumab) will become the first immunotherapy available for UK National Health Service (NHS) patients with an aggressive form of stomach cancer, after a regulatory nod from the National Institute of Health and Care Excellence (NICE).
NICE has recommended the drug for adults with stomach cancer that has not spread extensively and can be removed through surgery. This includes gastric and gastro-oesophageal junction cancers, which are frequently diagnosed at an advanced stage. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
